Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
NEW YORK, Feb. 10, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation (“MannKind” or the “Company”) (Nasdaq:MNKD) between August 10, 2015 and January 5, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired MannKind securities between August 10, 2015 and January 5, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
